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Determinants of human papillomavirus (HPV)-16 serological conversion and persistence were assessed in a population-based cohort
of 10049 women in Guanacaste, Costa Rica. Serologic responses to HPV-16 were measured in 7986 women by VLP-based enzyme-
linked immunosorbent assay at both study enrolment (1993/94) and at 5–7 years of follow-up. Seropositive women were defined as
X5 standard deviations above the mean optical density obtained for studied virgins at enrolment (n¼573). Seroconnversion
(n¼409), persistence (n¼675), and clearance (n¼541) were defined based on enrolment and follow-up serology measurements.
Age-specific distributions revealed that HPV-16 seroconversion was highest among 18- to 24-year-old women, steadily declining with
age; HPV-16 seropersistence was lowest in women 65þ years. In age-adjusted multivariate logistic regression models, a 10-fold risk
increase for HPV-16 seroconversion was associated with HPV-16 DNA detection at enrolment and follow-up; two-fold risk of
seroconversion to HPV-16 was associated with increased numbers of lifetime and recent sexual partners and smoking status.
Determinants of HPV-16 seropersistence included a 1.5-fold risk increase associated with having one sexual partner during follow-up,
former oral contraceptive use, and a 3-fold risk increase associated with HPV-16 DNA detection at both enrolment and follow-up.
Higher HPV-16 viral load at enrolment was associated with seroconversion, and higher antibody titres at enrolment were associated
with seropersistence.
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Most genital human papillomavirus (HPV) infections are transient:
within 2 years of incident infection, HPV DNA becomes
undetectable in approximately 90% of women (Ho et al, 1995).
Moreover, not all women infected with HPV seroconvert; only
about half of all HPV DNA-positive women test positive for
corresponding type-specific antibodies using available assays
(Kirnbauer et al, 1994; Le Cann et al, 1995). For those women
who have seroconverted, however, detection of serum antibodies
to HPV capsids is a valid marker of current and past type-specific
HPV exposure (Wideroff et al, 1995, 1999; Carter et al, 1996;
Sasagawa et al, 1998; Touze et al, 2001).
We previously reported population-based seroprevalence of HPV-
16, -18, -31, and -45 in our 10000 women population-based study in
Costa Rica at enrolment; we confirmed the waning detection of HPV
antibodies with age and the determinants of seroprevalence to
include increasing lifetime number of sexual partners and smoking
(Wang et al, 2003), as similarly reported in other prevalence studies
(Stone et al, 2002; Nonnenmacher et al, 2003).
To extend our cross-sectional findings, we have now completed
HPV-16 serology measurements at a second time point, after 5–7
years of follow-up. Human papillomavirus 16 was selected because it
accountsfor the majority ofcervicalcancersworldwide (Munozetal,
2003) and is the focus of immunology and vaccinology research
(Lowy and Frazer, 2003). To further our understanding of HPV
serology in the natural history of cervical cancer, we report here the
epidemiologic characteristics and determinants of HPV-16 serologic
conversion and persistence in our Guanacaste, Costa Rica cohort.
METHODS
Study population
This study was conducted in the population-based cohort of 10049
women in Guanacaste, Costa Rica. As previously described, study
enrolment was conducted in 1993–94 with approval from the NCI
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yand local institutional review boards (Herrero et al, 1997;
Hildesheim et al, 2001; Bratti et al, 2004). Briefly, the cohort was
a representative sample of the adult female population in
Guanacaste, Costa Rica in 1993–94. Of 10738 women eligible for
the study, 10049 were interviewed (94%); refusals were women
who did not show up for their appointment despite multiple
invitations. At enrolment, study participants completed a risk
factor questionnaire that addressed demographic characteristics
and behavioural and reproductive practices. Follow-up of the
cohort was conducted for 5–7 years until cohort exit, which began
in 2000. For the present analysis, follow-up data were available for
8084 women; the median length of follow-up was 6.4 years. In the
present analysis, a histologic diagnosis of CIN3 or cancer during
follow-up (n¼75) was considered the reference standard of
serious, newly diagnosed high-grade disease. Plasma specimens
collected from women at enrolment and at the end of follow-up
(concurrently at the time of diagnosis for cases) were used for
measurement of serologic responses to HPV-16. Of the 10049
women enrolled in the cohort, serology results from enrolment
specimens were obtained for 9951 women. Of the 8084 women
selected for follow-up (women with hysterectomies or prevalent
high-grade neoplasia were not followed) (Bratti et al, 2004), plasma
samples were obtained from 8058 women. However, of the 8058
women with plasma at follow-up, 72 women did not have plasma at
enrolment. Our final analytic population thus included 7986
women for whom plasma was available at both time points.
Serological measurements
Plasma samples collected at study enrolment and at the end of
follow-up were tested for anti-HPV L1 antibodies (IgG) at the
Johns Hopkins Medical Institutions by a VLP-based enzyme-
linked immunosorbent assay (ELISA) for HPV-16. Serology
measurements were conducted as previously described (Wang
et al, 2003). Briefly, each batch comprised approximately 2000–
3000 specimens, including intra- and interbatch reliability repeat
specimens and random samples of 200 virgins in the study
population, which permitted the calculation of batch-specific
serology cut-points (see below).
Human papillomavirus DNA testing
Cervical cytologic specimens collected using a Dacron swab at
enrolment and follow-up were tested for HPV DNA using L1
MY09/MY11 consensus primer methods, with TaqGold polymerase
and dot-blot typing, as previously described (Herrero et al, 2000).
The results for HPV-16 testing were available for 7367 women
included in the present analysis, because virgins did not undergo
pelvic examinations at enrolment.
Statistical methods
Consistent with our previous analysis, serology results were
dichotomised as antibody positive or negative (Wang et al,
2003). Women whose mean optical density (OD) measurements
were five standard deviations above that obtained for the
concurrently tested virgins (minus outliers in the virgin OD
distribution) were categorised as seropositive. All other women
below the five standard deviation cut-point were defined as
seronegative. This definition of seronegative women included, at
enrolment, 3110 women above and 5307 women below one
standard deviation of study virgins; at follow-up, this definition
included 1470 women above and 5495 women below one standard
deviation of study virgins. The cutoff was calculated independently
for each test batch, by comparison to the distribution of the values
obtained for the concurrently tested virgins in that batch (n¼200).
To demonstrate that our results were robust, we also compared
seropositive women to seronegative women, defined as less than
one standard deviation from studied virgins.
Defining serologic outcomes The enrolment population was first
dichotomised as HPV-16 seropositive (n¼1534) and seronegative
(n¼8417). Of the 1216 (79%) HPV-16 seropositive women with
follow-up data, 675 (55.5%) remained seropositive at follow-up
and 541 (44.5%) tested seronegative (Table 1). Of the 6770 (80%)
HPV-16 seronegative women at enrolment with follow-up data, 409
(6%) seroconverted and 6361 (94%) remained seronegative
(Table 1). We identified determinants of seroconversion by
comparing the 409 women who seroconverted to the 6361 who
remained seronegative. Likewise, we identified determinants of
seropersistence by comparing the 675 women who remained
seropositive at follow-up to the 541 who became seronegative.
Age-specific distributions of seroconversion, serologic persis-
tence, and serologic clearance were graphically compared with
age category in years (18–24, 25–29, 30–44, 45–64, 65þ years).
Age was calculated as the woman’s age at the midpoint of her
follow-up.
Determinants of serologic status All HPV cofactors reported
previously in Costa Rica (Hildesheim et al, 2001) were thoroughly
investigated with regard to serologic outcomes. Specifically,
univariate associations for both outcomes (seroconversion and
seropersistence) were assessed for the following behavioural and
reproductive variables assessed at enrolment and follow-up via
questionnaire: number of sexual partners (lifetime at enrolment,
and recent, defined as during the follow-up period and thus
includes both previous and new partners), use of oral contra-
ceptives (OCs) (never, former, current), smoking status (never,
former, current), early age at first intercourse (defined as o16
years), number of live births and number of pregnancies (lifetime
at enrolment and recent, defined as during the follow-up period),
years between menarche and sexual debut, and self-reported
sexually transmitted diseases. For smoking and OC use, a
combined variable was constructed from enrolment and follow-
up data (e.g. enrolment/follow-up – never/never, former/former,
current/current, never/current, current/former, former/current).
Odds ratio estimates with 95% confidence intervals (CIs) were
obtained to assess the magnitude and statistical significance of the
associations between these variables and HPV serostatus. Presence
of HPV-16 DNA at enrolment and follow-up was also assessed
considering all combinations for DNA status (e.g. enrolment/
follow-up – negative/negative, negative/positive, positive/negative,
positive/positive).
We assessed HPV-16 semiquantitative viral load and the OD for
serological measurement at enrolment as potential determinants of
HPV seroconversion and seropersistence. Specifically, we assessed
whether women with higher OD measurements at enrolment were
more likely to remain seropositive at follow-up, and whether
higher HPV-16 viral load at enrolment, as measured by signal
Table 1 Definition of study outcomes: HPV-16 seroconversion,
seroclearance, and seropersistence
Serology measurement
Enrolment Follow-up
Enrolment and
follow-up
HPV-16 serological
status
(n¼9951) (n¼8058) (n¼7986)
Negative   6361
Clearance +   541
Conversion   + 409
Persistence + + 675
HPV-16 seroconversion, persistence, and clearance
SS Wang et al
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seropersistence.
Variables independently and statistically significantly associated
with seroconversion or seropersistence in our univariate analyses
were included in our final multivariate models; they included
number of lifetime sexual partners reported at enrolment (1, 2–3,
4þ), number of sexual partners during follow-up (0, 1, 2þ),
smoking (never/never, never/current, current/current, current/
former, former/former, former/current), OC use (never/never,
never/current, current/current, current/former, former/former,
former/current), and HPV-16 DNA status (positive/positive,
positive/negative, negative/positive, negative/negative) as mea-
sured by PCR. Our final model also adjusted for age at the
midpoint of the woman’s follow-up (years), and serology batch.
We excluded women who remained virgins throughout the
duration of study follow-up (n¼273).
Finally, the age-adjusted association between HPV-16 DNA and
serological status among the 75 women with a CIN3/cancer
diagnosis during study follow-up was assessed (odds ratio and
95% CI). For these cases, the follow-up testing was carried out at
the time of diagnosis before treatment. CIN3/cancers diagnosed at
enrolment were censored for follow-up and did not have a second
time point for which serology measurements were made; thus, they
were excluded from all analyses. Statistical analyses were
conducted on SAS 8.2 for Windows and STATA 7.0.
RESULTS
Seroprevalence of HPV-16 at both cross-sectional time points
(enrolment in 1993–94, and follow-up in 2000) was 15%. In all,
55% (675 of 1216) of women seropositive at enrolment remained
seropositive for HPV-16 at follow-up, while 6% (409 of 6770) of
initially HPV-16 seronegative women were seropositive at the time
of follow-up. As shown in Figure 1, serologic status varied by age.
Of women seronegative at enrolment, seroconversion was highest
in women 18–24 years old and steadily declined with increasing
age. Of women seropositive at enrolment, HPV-16 serologic
persistence was above 50% for all age groups except in women
65 years and older.
Determinants of HPV-16 seroconversion
Univariate analyses for determinants of HPV-16 seroconversion,
compared to women who remained seronegative, revealed a
number of potential determinants, which were subsequently
included in the final multivariate logistic regression model. After
adjustment for age and serology batch, and excluding women who
remained virgins for the duration of the cohort study, two or more
lifetime number of sexual partners and one or more sexual partner
(not necessarily new partners) during study follow-up were
statistically significantly associated with an increased risk for
seroconversion (Table 2). It is important to note that when
stratified by lifetime number of sexual partners, one or more
sexual partners during study follow-up remained associated with
risk for seroconversion; likewise, when stratified by number of
sexual partners during follow-up, two or more lifetime number of
sexual partners reported at enrolment also remained significantly
associated with risk for seroconversion. Compared to never
smokers, a 2.8-fold increase in risk is observed for women who
were smokers at enrolment and former smokers at the time of
follow-up; no other category of smoking increased risk for
seroconversion. Finally, women HPV-16 DNA positive at enrol-
ment and at follow-up possessed the highest level of risk for HPV-
16 seroconversion with an odds ratio of 10.0 (95% CI: 4.5–22.2),
followed by a 6.4-fold risk increase for women who were initially
HPV DNA negative but positive at follow-up, and a three-fold risk
increase for women who were HPV DNA positive at enrolment and
negative at follow-up; all were statistically significant.
Determinants of HPV-16 seropersistence
Univariate analyses of women with serologic persistence, com-
pared to women who were seronegative at follow-up, demonstrated
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Figure 1 Age distribution of HPV-16 seroconversion and persistence in
Guanacaste, Costa Rica women at midpoint age (years) during follow-up.
Table 2 Final logistic regression model demonstrating the association
between recent and lifetime number of sexual partners, smoking status, and
HPV-16 DNA status with HPV-16 seroconversion in the Guanacaste Study
(n¼6587), adjusting for age and serology batch, and excluding virgins
Determinants of
HPV-16
seroconversion
HPV-16
seroconversion
(n¼400)
a (no.
(%))
Remained
seronegative
(n¼6128)
a
(no. (%)) OR (95% CI)
Lifetime number of sexual partners at enrolment
0–1 (referent) 17 (4.5) 3707 (95.5) 1.0
2–3 144 (8.7) 1512 (91.3) 1.9 (1.5–2.4)
4+ 39 (11.0) 317 (89.0) 1.9 (1.3–2.9)
Number of sexual partners during follow-up
0 (referent) 219 (4.9) 4282 (95.1) 1.0
1 82 (8.4) 891 (91.6) 1.5 (1.1–2.0)
2+ 56 (13.5) 358 (86.5) 2.2 (1.6–3.1)
Smoking
Never/never (referent) 341 (5.9) 5437 (94.1) 1.0
Never/current 6 (8.6) 64 (91.4) 1.1 (0.5–2.6)
Current/current 11 (6.0) 171 (94.0) 0.7 (0.4–1.4)
Current/former 20 (16.8) 99 (83.2) 2.8 (1.7–4.8)
Former/former 11 (3.9) 273 (96.1) 0.7 (0.4–1.3)
Former/current 2 (8.7) 21 (91.3) 1.2 (0.3–5.3)
Oral contraceptive use
Never/never (referent) 106 (5.1) 1970 (94.9) 1.0
Never/current 10 (10.6) 84 (89.4) 1.3 (0.6–2.6)
Current/current 41 (7.5) 505 (92.5) 1.0 (0.7–1.6)
Current/former 51 (6.9) 684 (93.1) 1.0 (0.7–1.5)
Former/former 139 (5.6) 2342 (94.4) 0.9 (0.7–1.2)
Former/current 22 (8.6) 233 (91.4) 1.1 (0.7–1.9)
HPV-16 status
Negative/negative 316 (5.4) 5516 (94.6) 1.0
Positive/negative 14 (16.3) 72 (83.7) 3.0 (1.6–5.5)
Negative/positive 31 (30.1) 72 (69.9) 6.4 (4.0–10.2)
Positive/positive 11 (37.9) 18 (62.1) 10.0 (4.5–22.2)
aNumbers in cells do not always equal total number due to missing values.
HPV-16 seroconversion, persistence, and clearance
SS Wang et al
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risk factors for seropersistence. After adjustment for age and
serology batch, and excluding women who remained virgins for
the entire study, multivariate analyses revealed that women
reporting one sexual partner during follow-up and those reporting
former OC use at both enrolment and follow-up had a 1.5-fold
statistically significant increase in risk for serologic persistence
(Table 3). In addition, women HPV-16 DNA positive at both
enrolment and follow-up had a 3.3-fold increase in risk for HPV-16
seropersistence followed by a 2.2-fold increase in risk for women
HPV-16 DNA positive at enrolment but negative at follow-up.
Further stratification by age (o30 and X30 years) did not alter
these results.
HPV-16 viral load and OD measurements
Increasing HPV-16 viral load at enrolment as measured by
qualitative PCR signal strength (weak vs strong, as assessed by
two observers with adjudication in case of disagreement) was also
associated with a significant higher odds ratio for HPV-16
seroconversion. Odds ratios were 3.0 (95% CI: 1.5–6.0) and 6.2
(95% CI: 3.5–11.1) for weak and strong HPV-16 PCR signal
strengths, respectively. Viral load did not appear to modify the risk
of seropersistence among HPV-16-positive women, with odds
ratios of 2.7 (95% CI: 1.2–6.4) and 2.2 (95% CI: 1.1–4.2) for weak
and strong signal strengths, respectively. Further stratification by
age also did not reveal differences. Further investigation of
determinants of serologic persistence also revealed that of women
seropositive at enrolment (e.g. five standard deviations above the
set cut-point), women with the highest mean OD measures at
enrolment were most likely to remain seropositive at follow-up, as
defined by the same cut-point. Specifically, 80% of women with the
highest quartile of mean OD seropersisted; these women possessed
a 12.7-fold increase in risk for seropersistence when compared to
seropositive women in the lowest quartile. In all, 5.8- and 2.0-fold
increases in risk for seropersistence were observed for women in
the third and second quartiles of mean OD, respectively. In the
third quartile of mean OD, 69% seropersisted, and in the second
quartile 44% seropersisted.
Association between serologic status and CIN3/cancer
Finally, we observed significant associations between serologic
status and disease outcome of CIN3/cancer diagnosed during
follow-up as shown in Table 4. Compared to women who were
HPV-16 seronegative at both time points, women who seroper-
sisted or seroconverted were at elevated risk for CIN3/cancer.
Women who became seronegative at follow-up were not at
significant increase in risk for CIN3/cancer. When restricted to
HPV-16 DNA-positive women as measured by PCR, risk associa-
tions between serology and disease were no longer statistically
significant.
DISCUSSION
In the present study, serologic status was a dynamic result of
seroconversion and clearance; only half of all seropositive women
were seropositive at both time points. In our previous cross-
sectional study, seroprevalence peaked at 35–44 years old (Wang
et al, 2003); in the present analysis, seropersistence was also
highest in this age group. Seroconversion was highest in women
18–24 years old and steadily declined with age. This pattern
mirrored HPV DNA age curves we reported previously, with a
peak at youngest age groups and declining with age (Wang et al,
2003). Although of interest, detailed assessment of HPV DNA and
serological status particularly in older age groups could not be
assessed due to small numbers in these older age groups.
Nevertheless, age-specific patterns of HPV-16 serologic conversion
and persistence support the known waning of serological response
with age and time.
In women identified as HPV-16 DNA positive at enrolment, less
than half were HPV-16 seropositive at enrolment, consistent with
previous studies (Carter et al, 2000). Although an additional 13%
of seronegative women at enrolment were subsequently seroposi-
tive at follow-up, this could be the result of either HPV-16
infection identified at enrolment or from a subsequent infection
(e.g. with the same or different HPV-16 variant).
Determinants of seroconversion at follow-up were similar to the
determinants of seroprevalence we reported previously in our cross-
Table 3 Final logistic regression model demonstrating the association
between number of sexual partners during follow-up, former oral
contraceptive use, and HPV-16 DNA status for HPV-16 seropersistence
in the Guanacaste Study (n¼1205), adjusting for age and serology batch,
and excluding virgins
Determinants of
HPV-16
seropersistence
HPV-16
seropersistence
(n¼672)
a (no.
(%))
HPV-16
seroclearance
(n¼533)
a (no.
(%)) OR (95% CI)
Lifetime number of sexual partners at enrolment
0–1 (referent) 236 (53.3) 207 (46.7) 1.0
2–3 236 (56.1) 185 (43.9) 1.1 (0.8–1.4)
4+ 87 (57.6) 64 (42.4) 1.0 (0.7–1.5)
Number of sexual partners during follow-up
0 (referent) 377 (53.6) 326 (46.4) 1.0
1 122 (62.9) 72 (37.1) 1.5 (1.0–2.1)
2+ 56 (49.6) 57 (50.4) 0.8 (0.5–1.3)
Smoking
Never/never (referent) 548 (54.7) 454 (45.3) 1.0
Never/current 11 (73.3) 4 (26.4) 2.7 (0.9–8.9)
Current/current 31 (62.0) 19 (38.0) 1.4 (0.8–2.6)
Current/former 21 (58.3) 15 (41.7) 1.3 (0.7–2.7)
Former/former 45 (59.2) 31 (40.8) 1.3 (0.8–2.1)
Former/current 7 (70.0) 3 (30.0) 1.6 (0.4–6.6)
Oral contraceptive use
Never/never (referent) 181 (51.4) 171 (48.6) 1.0
Never/current 7 (58.3) 5 (41.7) 0.9 (0.2–3.0)
Current/current 56 (47.9) 61 (52.1) 0.8 (0.5–1.3)
Current/former 86 (54.0) 73 (46.0) 1.0 (0.7–1.6)
Former/former 309 (61.3) 195 (38.7) 1.5 (1.1–2.1)
Former/current 21 (55.3) 17 (44.7) 1.2 (0.6–2.4)
HPV-16 status
Negative/negative 583 (54.7) 482 (45.3) 1.0
Positive/negative 36 (70.6) 15 (29.4) 2.2 (1.2–4.1)
Negative/positive 7 (63.6) 4 (36.4) 1.2 (0.3–4.3)
Positive/positive 22 (78.6) 6 (21.4) 3.3 (1.3–8.4)
aNumbers in cells do not always equal total number due to missing values.
Table 4 Association between HPV-16 seroconversion, seroclearance,
and seropersistence with development of CIN3/cancer during follow-up
HPV-16
serological
status Enrolment
Follow-
up
a
CIN3/cancer
Total n
b n OR (95% CI)
Negative    5765 42 (0.7%) 1.0 (referent)
Clearance +   501 5 (1.0%) 1.4 (0.5–3.5)
Conversion   + 384 12 (3.1%) 4.4 (2.3–8.4)
Persistence + + 631 16 (2.5%) 3.6 (2.0–6.3)
aFollow-up serology measurement is concurrent with time of disease diagnosis.
bDoes not equal 7986 due to missing outcome variables.
HPV-16 seroconversion, persistence, and clearance
SS Wang et al
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consistent with other populations (Stone et al, 2002; Nonnenmacher
et al, 2003); recent and lifetime number of sexual partners
and smoking behaviour remained associated with seroconver-
sion. Curiously, increased risk appeared to be especially elevated
among women who were current smokers at enrolment but
former smokers at the time of follow-up, potentially suggesting
temporality related to smoking behaviour, its concurrence with
HPV exposure, and subsequent detection of antibodies. As expected,
the highest risk for seroconversion was observed for women
HPV-16 DNA positive both at enrolment and at follow-up. Women
HPV-16 DNA positive at enrolment but negative at follow-up
exhibited the next highest level of risk for seroconversion,
supporting the notion that HPV antibody detection is a marker of
past infection.
Determinants for seropersistence included having one sexual
partner during the follow-up period and former OC use. For
reasons that are not clear, having two partners during follow-up
was not associated with seropersistence; continued HPV
exposure (and possibly re-exposure) with the same HPV type
and resultant antigenic stimulation is to be investigated in a
more refined analysis of HPV DNA typing for all years of
follow-up. We also found that for seropositive women, a higher
OD at enrolment was associated with seropersistence at
follow-up, consistent with a previous study in which HPV
antibodies persisted when initial levels were high or when
there was continued exposure (Ho et al, 2004). It is unclear
why former OC use was associated with increased risk for
seropersistence. Although former OC users were older, our
analysis was adjusted for age, and separate analyses stratified by
age did not demonstrate differences; former OC use was not
related to mean OD levels.
Although IgG seroconversion against HPV-16 has been reported
within 6–12 months of infection (Wikstrom et al, 1995; Carter et al,
2000), the duration of serologic detection (e.g. being seropositive)
remains unclear (Stone et al, 2002). Reported to be high over a
long period of time (van Doornum et al, 1998), serology measures
are likely to be confounded by repeated exposure to HPV-16 (Onda
et al, 2003). Persistence of HPV-16 antibodies has been found
for 7–13 years (Shah et al, 1997) and for 4 years in a study of
1656 pregnant women who demonstrated stable antibody levels
(af Geijersstam et al, 1998). We defined seropersistence as two
high positive antibody measurements at enrolment and at
follow-up, that is, for a median duration of over 6 years. Because
serology was only assessed at two time points, we could not
assess the duration of the serologic response or its determinants.
Further investigation of multiple, longitudinal measurements of
HPV infection assessed by both serology and DNA testing during
the 5–7 years of follow-up is likely to provide additional
clues regarding seropersistence.
Several studies have reported a 2–3-fold magnitude of risk for
cervical cancer for HPV seropositive women, compared to
seronegative women (Nonnenmacher et al, 1995, 1996; Chua et al,
1996; Wideroff et al, 1996; Dillner et al, 1997; Sigstad et al, 2002).
In this study, we found that seropositive women who are
seronegative by follow-up are not at increased risk for CIN3/
cancer. On the contrary, women who seroconvert or are
seropersistent possessed the highest risk for CIN3/cancer. How-
ever, the lack of association when restricted to HPV-16 DNA-
positive women suggests the overwhelming association between
HPV DNA and disease.
Limitations of our study include the necessity for a high cutoff
(five standard deviations above mean for studied virgins) to define
HPV-16 seropositive women. Because VLP ELISAs are still prone
to misclassification including false positives, we chose to define
HPV-16 seropositive women stringently, thus probably misclassi-
fying some HPV-16 seropositive women (seroconverters or
seropersisters) as seronegative and biasing our results towards
the null. However, we attempted to measure the accuracy of our
definition of seropersistence by a small subset of approximately
1500 women, and measurements were conducted 1 year after
enrolment. While the majority of women defined as seropersistent
(based on enrolment and 5–7 years of follow-up) were also
seropositive at 1 year after enrolment, approximately 10% were
not. This probably reflects misclassification in our definition of
seropersistence and might also have further biased our results
towards the null.
To our knowledge, this is the largest population-based
seroprevalence study of HPV-16 with follow-up serology data.
Our subjects were representative of the adult female population of
Guanacaste, Costa Rica and our results provide a detailed
description of serologic status in this and population behavioural
factors likely to influence long-term serologic status. The known
waning of HPV antibody detection with age is confirmed,
attributed to both decline in seroconversion and seropersistence;
these age-specific data may be relevant to future plans for HPV
vaccination. Because antibody titres after natural infection are
lower than those following vaccination, these immunologic
responses should be distinguishable. Future analysis assessing
longitudinal HPV DNA status in relation to serologic status will be
important for clarifying the role that transient and persistent HPV
infections play in initiating and sustaining a humoral immune
response.
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